Dydrogesterone

GENITO URINARY SYSTEM AND SEX HORMONES

Key facts

Dydrogesterone is an ofm drug catalogued in DrugCentral. It was first approved by the PMDA in 1965. DrugCentral lists 2 molecular targets, including PGR and NR2E1. Recorded indications include Luteal phase support and Prevention of premature ovulation during controlled ovarian stimulation.

• Approval status: ofm (first approved 1965 by the PMDA).
• Molecular targets: PGR and NR2E1 (2 listed in DrugCentral).
• Indications: Luteal phase support and Prevention of premature ovulation during controlled ovarian stimulation.
• ATC code: G03DB01 (Pregnadien derivatives).
• Molecular formula: C21H28O2; molecular weight 312.45 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Luteal phase support
• Prevention of premature ovulation during controlled ovarian stimulation

Mechanism & targets

Molecular targets (2)

Target	Gene	Action	Activity
Progesterone receptor	PGR	agonist	Ki 6.90
Nuclear receptor subfamily 2 group E member 1	NR2E1	unknown	Kd 4.56

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
1965-12-01	PMDA	—	—
—	FDA	—	SOLVAY

ATC classification

ATC code	Therapeutic hierarchy
G03DB01	GENITO URINARY SYSTEM AND SEX HORMONES › SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM › PROGESTOGENS › Pregnadien derivatives
G03FA14	GENITO URINARY SYSTEM AND SEX HORMONES › SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM › PROGESTOGENS AND ESTROGENS IN COMBINATION › Progestogens and estrogens, fixed combinations
G03FB08	GENITO URINARY SYSTEM AND SEX HORMONES › SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM › PROGESTOGENS AND ESTROGENS IN COMBINATION › Progestogens and estrogens, sequential preparations

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Abortion spontaneous	453.8
Maternal exposure during pregnancy	396.5
Ovarian hyperstimulation syndrome	271.5
Placenta accreta	81.1
Exposure during pregnancy	63.3
Premature baby	60.6

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Dydrogesterone is on its molecule page.

• Molecular formula: C₂₁H₂₈O₂
• Molecular weight: 312.45 g/mol
• CAS number: 152-62-5
• InChIKey: JGMOKGBVKVMRFX-HQZYFCCVSA-N
• PubChem CID: 9051

CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Dydrogesterone used for?

DrugCentral lists the following indications for Dydrogesterone: Luteal phase support and Prevention of premature ovulation during controlled ovarian stimulation.

How does Dydrogesterone work?

Its molecular targets in DrugCentral include PGR (agonist) and NR2E1.

When was Dydrogesterone first approved?

Dydrogesterone was first approved by the PMDA in 1965.

What is the chemical formula of Dydrogesterone?

Dydrogesterone has the molecular formula C21H28O2 and a molecular weight of 312.45 g/mol.

Sources

• DrugCentral drug card 975 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200853 — compound record and bioactivity
• PubChem CID 9051 — chemical identifiers
• DrugBank DB00378 — drug record
• FDA UNII 90I02KLE8K — substance identity
• DailyMed: FDA labels for Dydrogesterone — current prescribing information (label search)
• UniProt P06401 (PGR) — target protein
• UniProt Q9Y466 (NR2E1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.